Nona Biosciences, a subsidiary of HBM Holdings Limited, has joined forces with ExeVir Bio in a collaboration that promises to revolutionize the development of treatments for unmet needs in infectious diseases.
By combining their extensive experience and cutting-edge technology, both companies are committed to utilizing the I to I™ approach in order to bring these innovative therapies to life. With this powerful partnership, Nona Biosciences and ExeVir Bio are poised to make a real difference in the lives of patients who desperately need it.
Dr. Jingsong Wang, Chairman of Nona Biosciences, is optimistic that their joint foray into antibody engineering and infectious diseases research will bring us one step closer to eradicating some of the most difficult and persistent diseases. With the combination of their expertise in these two areas, there is hope for groundbreaking discoveries that will revolutionize the field.
Dr. Torsten Mummenbrauer, CEO of ExeVir, is thrilled to announce their collaboration with Nona Biosciences, which will provide them with invaluable support in their mission to create groundbreaking treatments for infectious diseases. This collaboration will open up a world of possibilities, significantly expanding ExeVir’s pipeline in infectious diseases and bringing much-needed relief to patients everywhere.
About Nona Biosciences
Nona Biosciences, a global biotechnology firm owned by HBM Holdings (HKEX: 02142), is revolutionizing the healthcare industry with its cutting-edge technology and total solution from “Idea to IND” (I to I™ ).
Our integrated antibody and antibody-related discovery services combine multiple modalities from antigen preparation to preclinical research, leveraging the power of Harbour Mice® platforms and our highly-experienced therapeutic antibody discovery team. With Nona Biosciences, you get access to a comprehensive solution for maximum efficiency and effectiveness.
Harbour Mice® is revolutionizing the creation of monoclonal antibodies, offering a full range of human H2L2 and HCAb formats. Thanks to the integrated technology platform of Nona Biosciences, we are now able to unlock the potential of these powerful drugs and create next-generation treatments that bring hope to millions around the world.
About ExeVir Bio
ExeVir Bio is revolutionizing the fight against infectious diseases with its innovative llama-derived antibody (VHH) technology platform.
Through the development of single-domain antibody based therapeutics, the company is actively pursuing prophylactic and therapeutic solutions to combat COVID-19 for immunocompromised populations, including those undergoing active chemotherapy, immunosuppressive drug therapy, solid organ transplantation, hematological malignancies, and AIDS patients, who face a high unmet need due to the limitations of existing vaccines and treatments.
ExeVir’s COVID-19 pipeline is revolutionizing the fight against the virus with its state-of-the-art combination product, XVR012. This cutting-edge bi-specific single-domain-based antibody construct takes aim at two conserved epitopes in the S1 subunit, as well as several additional S1 and S2 epitopes, all in one powerful product.
ExeVir, a spin out of VIB, the renowned Belgium-based life sciences research institute, has secured a staggering EUR 42 million in series A funding from Fund+ and an international consortium of investors, including UCB Ventures, FPIM, V-Bio Ventures, VIB, SRIW, Noshaq, Vives IUF and SambrInvest.
On top of this, ExeVir has also received non-dilutive funding support from VLAIO, the SPW-Recherche and the European Union, totalling €16.5M. Furthermore, in 2023, the company secured an option for EUR 25 million venture debt financing from the European Investment Bank.